AKBA - Akebia Therapeutics, Inc.
| Previous Close | 6.92 |
| Open | 6.91 |
| Bid | 6.71 x 4000 |
| Ask | 6.87 x 1000 |
| Day's Range | 6.52 - 6.95 |
| 52 Week Range | 5.20 - 11.60 |
| Volume | 1,558,416 |
| Avg. Volume | 1,215,990 |
| Market Cap | 785.889M |
| Beta (3Y Monthly) | 2.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.47 |
| Earnings Date | May 7, 2019 - May 13, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.30 |
- Zacks•9 days ago
Akebia Expands Vadadustat Licensing Deal With Vifor Pharma
Akebia Therapeutics (AKBA) and Vifor Pharma expand licensing agreement related to commercialization of Akeba's pipeline candidate, vadadustat, to include additional dialysis organizations.
- Business Wire•10 days ago
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
The Vifor Pharma Group (VIFN.VX) and Akebia Therapeutics, Inc. (AKBA) today announced that the companies have amended the terms of their license agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in the United States, subject to its approval by the U.S. Food and Drug Administration (FDA). Under the terms of the agreement signed in May 2017, Akebia granted Vifor Pharma a license to sell vadadustat to Fresenius Medical Care North America for use solely within its dialysis clinics in the U.S., subject to FDA approval.
- Business Wire•10 days ago
Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement
The Vifor Pharma Group (SIX:VIFN) and Akebia Therapeutics, Inc. (AKBA) today announced that the companies have amended the terms of their licence agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in the United States, subject to its approval by the U.S. Food and Drug Administration (FDA). Under the terms of the agreement signed in May 2017, Akebia granted Vifor Pharma a licence to sell vadadustat to Fresenius Medical Care North America for use solely within its dialysis clinics in the U.S., subject to FDA approval.
- Business Wire•14 days ago
Akebia Therapeutics to Present at the 18th Annual Needham Healthcare Conference
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced that John P. Butler, President and Chief Executive Officer, will present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019 at 11:20 a.m. Eastern Time in New York. A live webcast of the presentation will be available on the company’s website at www.akebia.com. Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease.
- Business Wire•17 days ago
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted 16 newly-hired employees options to purchase an aggregate of 225,000 shares of Akebia’s common stock on March 29, 2019, as inducements material to each such employee’s entering into employment with Akebia. The options have an exercise price of $8.19 per share, which is equal to the closing price of Akebia’s common stock on the grant date. Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with the company.
- CNW Group•18 days ago
Medison to Nominate Six Highly Qualified Directors for Knight Therapeutics' Board to Strengthen Oversight and Drive Value Creation for All Shareholders
PETACH TIKVA, Israel , April 1, 2019 /CNW/ - Medison Biotech (1995) Ltd. ("Medison"), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics, Inc. (GUD.TO) ("Knight" or the "Company"), today announced that it has nominated six exceptional pharmaceutical industry leaders (the "Nominees") for election to Knight's Board of Directors (the "Board") at the Company's 2019 annual general meeting, in accordance with the Company's Advanced Notice By-Law. Other than Medison's CEO, Meir Jakobsohn, who has served on the Knight Board since 2015, none of the Nominees has any ties to Knight or Medison.
- GlobeNewswire•23 days ago
Consolidated Research: 2019 Summary Expectations for ADT, HudBay Minerals, Whirlpool, Akebia Therapeutics, Nevro, and MicroStrategy — Fundamental Analysis, Key Performance Indications
NEW YORK, March 27, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GuruFocus.com•24 days ago
Akebia Therapeutics Inc (AKBA) Files 10-K for the Fiscal Year Ended on December 31, 2018
Akebia Therapeutics Inc is a biopharmaceutical company. Akebia Therapeutics Inc had annual average EBITDA growth of 19.90% over the past five years. Warning! GuruFocus has detected 2 Warning Signs with AKBA.
- Thomson Reuters StreetEvents•29 days ago
Edited Transcript of AKBA earnings conference call or presentation 18-Mar-19 8:30pm GMT
Q4 2018 Akebia Therapeutics Inc Earnings Call
Motley Fool•last monthAkebia Therapeutics (AKBA) Q4 2018 Earnings Conference Call Transcript
AKBA earnings call for the period ending December 31, 2018.
- Business Wire•last month
Akebia Therapeutics Announces Preliminary Full-Year 2018 Financial Results and Business Highlights
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced preliminary financial results for the full year ended December 31, 2018 and business highlights. “We successfully executed a number of strategic initiatives to advance our mission, and with the recent completion of our merger with Keryx, we have emerged as a leading, fully-integrated renal company with the potential to greatly improve care for patients with kidney disease. Mr. Butler continued, “With respect to vadadustat, our lead product candidate, we believe that it has the potential to set a new standard of care for patients with anemia due to chronic kidney disease with a differentiated clinical profile.
- Market Realist•last month
MannKind or Akebia: Who’s Expected to Report Faster EPS Growth?
MannKind or Akebia: Which Is a Better Biotech Pick This Month?(Continued from Prior Part)Financial performance In the fourth quarter, MannKind Corporation (MNKD) reported revenue of $16.03 million, a YoY (year-over-year) rise of 253.91%. According
Market Realist•last monthMNKD or AKBA: Which Is Expected to Report Faster Revenue Growth?
MannKind or Akebia: Which Is a Better Biotech Pick This Month?(Continued from Prior Part)Growth trendsIn its fourth-quarter earnings investor presentation, MannKind Corporation (MNKD) announced that Afrezza had seen fiscal 2018 net sales of $17.3
- Market Realist•last month
What Analysts Are Recommending for MannKind and Akebia in March
MannKind or Akebia: Which Is a Better Biotech Pick This Month?Share price movementsOn March 12, MannKind Corporation (MNKD) closed at $2.09, 8.29% higher than its previous closing price, 122.34% higher than its 52-week low of $0.94, and 31.25% lower
- Motley Fool•last month
Why Akebia Therapeutics, Momo, and Switch Jumped Today
Good news on several fronts helped lift many stocks.
- Motley Fool•last month
Why Akebia Therapeutics Is Soaring Today
Great news from two late-stage studies lit a fire under the biopharmaceutical stock.
- Benzinga•last month
The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 11) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ...
- Business Wire•last month
Akebia Therapeutics Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Vadadustat in Japanese Patients with Anemia Due to Chronic Kidney Disease
– Each Study Met Its Primary Endpoint –
- Zacks•last month
Analysts Estimate Akebia Therapeutics (AKBA) to Report a Decline in Earnings: What to Look Out for
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire•last month
Akebia Therapeutics to Host Fourth Quarter and Full-Year 2018 Investor Update Call and Webcast
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced it will host a fourth quarter and full-year 2018 investor update conference call and webcast at 4:30 p.m. Eastern Time on Monday, March 18, 2019. Individuals interested in participating in the call should dial (877) 458-0977 (U.S. and Canada) or (484) 653-6724 (international) using conference ID number 1376157. Beginning the morning of March 19, 2019, the call will be available for replay via telephone and the archived webcast will be available on Akebia’s website.
- Simply Wall St.•2 months ago
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Is Trading At A 29.34% Discount
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Today I will be providing a simple run through ofRead More...
GuruFocus.com•2 months agoSeth Klarman Disculoses 4th-Quarter Stock Purchases
Klarman starts four stakes, including in online auction site eBay Inc.
- GlobeNewswire•2 months ago
Report: Developing Opportunities within T-Mobile US, Noble, Akebia Therapeutics, Vornado Realty Trust, Bio-Rad Laboratories, and Standex International — Future Expectations, Projections Moving into 2019
NEW YORK, Feb. 04, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
